ProCE Banner Activity

Key Decisions in HIV Care: Assessing Candidacy for Long-Acting ART

Podcast Episodes
Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data about which patient factors may predict failure to LA CAB plus RPV and who is and who is not a good candidate for this new treatment option.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Faculty

Milena Murray

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.